Literature DB >> 26702066

Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.

Anthony R Mato1, Prioty Islam1, Catherine Daniel1, Lauren Strelec1, Adam H Kaye1, Sarah Brooks1, Alex Ganetsky1, Sunita Nasta1, David L Porter1, Jakub Svoboda1, Chadi Nabhan2, Stephen J Schuster1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26702066     DOI： 10.1182/blood-2015-12-686873

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

Review 1.  How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.

Authors:  Deborah M Stephens; John C Byrd
Journal:  Blood       Date:  2019-01-14       Impact factor: 22.113

Review 2.  Monitoring and Management of Toxicities of Novel B Cell Signaling Agents.

Authors:  Joanna Rhodes; Anthony Mato; Jeff P Sharman
Journal:  Curr Oncol Rep       Date:  2018-04-11       Impact factor: 5.075

3.  A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy.

Authors:  Sven Jungmann; Wolf-Dieter Ludwig; Nicolas Schönfeld; Torsten-Gerriet Blum; Claudia Großwendt; Christian Boch; Beate Rehbock; Sergej Griff; Alexander Schmittel; Torsten T Bauer
Journal:  Case Rep Oncol Med       Date:  2017-11-10

4.  Incidence, clinical characteristics, and outcome of interstitial pneumonia in patients with lymphoma.

Authors:  Wei Ping Liu; Xiao Pei Wang; Wen Zheng; Yan Xie; Mei Feng Tu; Ning Jing Lin; Ling Yan Ping; Zhi Tao Ying; Chen Zhang; Li Juan Deng; Ning Ding; Xiao Gan Wang; Yu Qin Song; Jun Zhu
Journal:  Ann Hematol       Date:  2017-10-31       Impact factor: 3.673

5.  Ibrutinib-induced severe liver injury.

Authors:  Amara G Nandikolla; Olga Derman; Deborah Nautsch; Qiang Liu; Hatef Massoumi; Sangeetha Venugopal; Ira Braunschweig; Murali Janakiram
Journal:  Clin Case Rep       Date:  2017-03-15

Review 6.  Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation.

Authors:  Babina Gosangi; Matthew Davids; Bhanusupriya Somarouthu; Francesco Alessandrino; Angela Giardino; Nikhil Ramaiya; Katherine Krajewski
Journal:  Cancer Imaging       Date:  2018-04-18       Impact factor: 3.909

Review 7.  Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).

Authors:  Georg Maschmeyer; Julien De Greef; Sibylle C Mellinghoff; Annamaria Nosari; Anne Thiebaut-Bertrand; Anne Bergeron; Tomas Franquet; Nicole M A Blijlevens; Johan A Maertens
Journal:  Leukemia       Date:  2019-01-30       Impact factor: 11.528

8.  Severe Hepatotoxicity due to Ibrutinib with a Review of Published Cases.

Authors:  Zaid H Tafesh; Morton Coleman; Clifton Fulmer; Jerry Nagler
Journal:  Case Rep Gastroenterol       Date:  2019-08-30

Review 9.  BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia.

Authors:  Lorenzo Falchi; Jessica M Baron; Carrie Anne Orlikowski; Alessandra Ferrajoli
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-02-10       Impact factor: 2.576

Review 10.  Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs.

Authors:  Candida Vitale; Maria Chiara Montalbano; Chiara Salvetti; Elia Boccellato; Valentina Griggio; Mario Boccadoro; Marta Coscia
Journal:  Cancers (Basel)       Date:  2020-01-23       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.